Alpa Laboratories share price
NSE: ALPABSE: 532878Pharmaceuticals & BiotechnologySmall Cap
Alpa Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2007
Last close ₹52.62up ₹0.42 (0.80%)BSE ₹52.60
Share price at the NSE close on 29 Oct 2026. Previous close ₹52.20.
29 Oct: open ₹51.00, high ₹53.20, low ₹51.00
52-week range of traded prices to 29 Oct 2026
₹46.10Low, 30 Mar 2026₹93.85High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹111 Cr2,659th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,88978.8% delivered
Results
Consolidated; ₹ crore.Alpa Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +0.5%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹24 Crdown 23.78%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹0.98 Crdown 29.10%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 4.1%
Revenue by quarter
Peak revenue ₹40 Cr, quarter to Mar 2025; lowest ₹19 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 1 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.9 | 26.2 | 39.9 | 19.1 | 26.3 | 29.0 | 31.4 | 23.9 |
| Net profit | 7.7 | 8.9 | −2.1 | 11.8 | 0.1 | 1.9 | 1.4 | 1.0 |
| Net margin | 30.8% | 34.0% | −5.3% | 61.6% | 0.4% | 6.6% | 4.4% | 4.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹106 Crdown 5.91%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹15 Crdown 23.04%
- Net margin
- 14.2%
Revenue by year
Peak revenue ₹112 Cr, year to Mar 2025; lowest ₹63 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66 | 63 | 78 | 86 | 98 | 112 | 92 | 109 | 112 | 106 |
| Net profit | 1 | 3 | 1 | 2 | 7 | 14 | 13 | 17 | 20 | 15 |
| Net margin | 1.4% | 4.5% | 1.0% | 2.2% | 7.4% | 12.6% | 13.7% | 15.4% | 17.3% | 14.2% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Drugs and Chemicals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Dividend yield is not shown: no dividend in the years on record.Alpa Laboratories PE ratio and valuation
Price to book
At or below today's level on 24% of 1,953 trading days since Nov 2018.
LowestHighest
Its median1.02Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −55.2% | −23.0% | −41.7% | 0.0% |
| 3 years | −4.8% | +5.9% | −10.1% | 0.0% |
| 5 years | +5.2% | +15.7% | −9.0% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Alpa Laboratories insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 1 off-market move
- Directors and key managers: no market trade · 1 off-market move
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Alpa Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Alpa Laboratories in market cap.Healthcare companies
Alpa Laboratories is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Godavari DrugsGODAVARI | 125 | 30.01 | 1.65 | +4.8% | +9.7% | 7.0% | 4.9% | 0.00% |
 Speciality MedicinesSPML | 125 | 9.57 | 1.75 | – | – | 18.3% | – | 0.00% |
 Sotac PharmaceuticalsSOTAC | 118 | 20.38 | 2.00 | +0.1% | −28.2% | 10.3% | – | 0.19% |
 Makers LaboratoriesMAKERSL | 114 | 33.21 | 1.56 | +17.6% | −61.6% | 4.8% | 11.1% | 0.00% |
 BALAXI PHARMACEUTICALSBALAXI | 109 | 44.88 | 0.44 | −5.9% | −87.2% | 1.0% | 2.1% | 0.00% |
 Tyche IndustriesTYCHE | 106 | 23.70 | 0.75 | −21.0% | −63.5% | 3.2% | −2.5% | 3.40% |
| Himalaya Nutravedics IndiaHNIL | 102 | – | – | – | – | – | – | 0.00% |
 Pharmaids PharmaceuticalsPHARMAID | 100 | – | 2.10 | +18.5% | – | −8.5% | −15.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Alpa Laboratories announcements
Oct 2026
12 Oct · Meeting
Sep 2026
30 Sep · Meeting
7 Sep · Corporate action
Alpa Laboratories share price by year
Each calendar year to 2025.Alpa Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 77.69 | −34.4% | 134.49 | 76.23 |
| 2024 | 118.46 | +14.7% | 139.20 | 74.60 |
| 2023 | 103.30 | +64.0% | 108.40 | 50.65 |
| 2022 | 63.00 | −20.7% | 106.00 | 49.30 |
| 2021 | 79.40 | +119.6% | 79.40 | 35.60 |
| 2020 | 36.15 | +113.9% | 47.60 | 11.80 |
| 2019 | 16.90 | −33.6% | 30.35 | 13.75 |
| 2018 | 25.45 | −40.0% | 52.35 | 23.55 |
| 2017 | 42.40 | +39.9% | 48.65 | 28.15 |
| 2016 | 30.30 | −60.2% | 77.90 | 27.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 51.95 | 52.89 | 51.00 | 52.20 | 51.90 | 7,190 | 72.4% |
| 27 Oct 2026 | 49.29 | 53.31 | 48.33 | 51.91 | 51.49 | 11,526 | 68.0% |
| 26 Oct 2026 | 49.28 | 49.28 | 46.85 | 48.36 | 48.26 | 15,162 | 73.0% |
| 23 Oct 2026 | 51.16 | 51.97 | 49.00 | 49.29 | 49.77 | 14,176 | 75.0% |
| 22 Oct 2026 | 52.00 | 52.90 | 49.50 | 51.46 | 51.68 | 7,598 | 71.6% |
| 21 Oct 2026 | 52.01 | 52.99 | 50.75 | 51.22 | 51.65 | 7,699 | 84.4% |
| 19 Oct 2026 | 51.01 | 54.28 | 51.01 | 52.25 | 52.71 | 5,277 | 74.0% |
| 16 Oct 2026 | 57.00 | 57.00 | 50.61 | 53.46 | 53.29 | 32,050 | 49.1% |
| 15 Oct 2026 | 59.00 | 59.00 | 55.60 | 55.96 | 56.55 | 9,093 | 75.8% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ALPA
- BSE code
- 532878
- ISIN
- INE385I01010
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.alpalabs.in
- CIN
- L85195MP1988PLC004446
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1988
- Registered office
- 33/2 Pigdamber, A B Road, Rau, Indore 453446, Madhya Pradesh
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments